Abstract

Keywords

Gene therapy in the CNS

LC Costantini¹, JC Bakowska², XO Breakefield² & O Isacson¹

Correspondence to: XO Breakefield, Massachusetts General Hospital East, Department Molecular Neurogenetics, 13th Street, Building 149, Charlestown, MA 02129, USA

Gene therapy for neurological disorder is currently an experimental concept. The goals for clinical utilization are the relief of symptoms, slowing of disease progression, and correction of genetic abnormalities. Experimental studies are realizing these goals in the development of gene therapies in animal models. Discoveries of the molecular basis of neurological disease and advances in gene transfer systems have allowed focal and global delivery of therapeutic genes for a wide variety of CNS disorders. Limitations are still apparent, such as stability and regulation of transgene expression, and safety of both vector and expressed transgene. In addition, the brain adds several challenges not seen in peripheral gene therapy paradigms, such as post-mitotic cells, heterogeneity of cell types and circuits, and limited access. Moreover, it is likely that several modes of gene delivery will be necessary for successful gene therapies of the CNS. Collaborative efforts between clinicians and basic researchers will likely yield effective gene therapy in the CNS. Gene Therapy (2000) 7, 93–109.

^© Macmillan Publishers Ltd 2000